EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Evolution of Liquid Biopsies for Detecting Pancreatic Cancer

Ryan Munnings iD, Peter Gibbs iD, Belinda Lee iD

Cancers · 29.09.2024 · 16 (19) · 3335

DOI: 10.3390/cancers16193335 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.09.2024. Verfasst von Ryan Munnings und 2 weiteren Autor:innen. Beteiligte Einrichtung: Walter & Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterised by late diagnosis and poor prognosis. Despite advancements, current diagnostic and prognostic strategies remain limited. Liquid biopsy techniques, including circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), circulating tumour exosomes, and proteomics, offer potential solutions to improve PDAC diagnosis, prognostication, and management. A systematic search of Ovid MEDLINE identified studies published between 2019 and 2024, focusing on liquid biopsy biomarkers for PDAC. A total of 49 articles were included. ctDNA research shows some promise in diagnosing and prognosticating PDAC, especially through detecting mutant KRAS in minimal residual disease assays. CTC analyses had low sensitivity for early-stage PDAC and inconsistent prognostic results across subpopulations. Exosomal studies revealed diverse biomarkers with some diagnostic and prognostic potential. Proteomics, although relatively novel, has demonstrated superior accuracy in PDAC diagnosis, including early detection, and notable prognostic capacity. Proteomics combined with CA19-9 analysis has shown the most promising results to date. An update on multi-cancer early detection testing, given its significance for population screening, is also briefly discussed. Liquid biopsy techniques offer promising avenues for improving PDAC diagnosis, prognostication, and management. In particular, proteomics shows considerable potential, yet further research is needed to validate existing findings and comprehensively explore the proteome using an unbiased approach.

Schlagwörter

Stichwörter der Autor:innen

cancer screeningcirculating tumour DNAcirculating tumour cellcirculating tumour exosomeliquid biopsypancreatic ductal adenocarcinomaproteomics

Autor:innen und Institutionen

  • Walter & Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
  • Department of Medical Biology, University of Melbourne, Parkville, VIC 3052, Australia.
  • Department of Medical Education, Melbourne Medical School, Parkville, VIC 3052, Australia.
  • Western Health, Footscray, VIC 3011, Australia.
  • Peter MacCallum Cancer Centre, Parkville, VIC 3052, Australia.
  • Northern Health, Epping, VIC 3076, Australia.

ORCID-Profile: Ryan Munnings, Peter Gibbs, Belinda Lee

Zitieren

APA

Munnings, R., Gibbs, P., & Lee, B. (2024). Evolution of Liquid Biopsies for Detecting Pancreatic Cancer. Cancers, 16(19), 3335. https://doi.org/10.3390/cancers16193335

Vancouver

Munnings R, Gibbs P, Lee B. Evolution of Liquid Biopsies for Detecting Pancreatic Cancer. Cancers. 2024;16(19):3335. doi:10.3390/cancers16193335

BibTeX
@article{Munnings2024,
  author = {Munnings, Ryan and Gibbs, Peter and Lee, Belinda},
  title = {Evolution of Liquid Biopsies for Detecting Pancreatic Cancer},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {19},
  pages = {3335},
  doi = {10.3390/cancers16193335}
}
Kostenlos starten →